硼中子俘获治疗在同位小鼠胶质瘤模型中实现肿瘤控制与神经保护双重疗效
本研究在GL261原位胶质瘤小鼠模型中评估硼中子俘获治疗(BNCT)的安全治疗窗与抗肿瘤机制。体外实验显示10B-BPA单独无细胞毒性,联合中子照射显著增强杀瘤效果;体内BNCT 250和500 mg/kg均比单纯中子照射更有效减轻肿瘤重量,但仅BNCT 250缓解运动障碍。BNCT 250在正常脑组织上调NeuN和BDNF,并通过Bax/Bcl-2/caspase级联诱导线粒体凋亡。
要点
- BNCT 250 mg/kg在控制肿瘤的同时减轻运动障碍并上调神经保护标志物。
- BNCT 500 mg/kg抗肿瘤更强但未缓解运动障碍,提示剂量需优化。
- BNCT通过升高Bax/Bcl-2比值、细胞色素c释放和caspase级联诱导凋亡。
核心结论
- 最佳BNCT方案通过Bax/Bcl2/caspase级联选择性触发肿瘤线粒体凋亡,同时在正常脑组织上调NeuN/BDNF。
- 本研究首次在体内验证BNCT兼具肿瘤控制与神经保护双重疗效。
研究设计与样本
- 体外:GL261细胞在不同10B-BPA浓度和中子照射时长下用CCK-8和克隆形成实验评估活力。
- 体内:建立GL261原位胶质瘤模型,评估肿瘤重量、生存分析、体重监测、硼生物分布(ICP-MS)、运动/认知功能及Western blotting。
主要发现
- 体外10B-BPA单独无细胞毒性,联合中子照射显著增强肿瘤细胞杀伤。
- 体内BNCT 250和BNCT 500 mg/kg比单纯中子照射更有效减轻肿瘤重量。
- 仅BNCT 250缓解小鼠运动障碍。
- 光子等效剂量估算:BNCT 250肿瘤/正常组织生物剂量为4.43/1.42 Gy-Eq,BNCT 500为8.46/2.57 Gy-Eq。
- BNCT 250显著增加正常脑组织NeuN和BDNF表达,并通过升高Bax/Bcl-2比值、诱导细胞色素c释放和激活caspase级联促进肿瘤凋亡。
关键数值与推荐
- BNCT 250 mg/kg对应肿瘤/正常组织生物剂量4.43/1.42 Gy-Eq。
- BNCT 500 mg/kg对应肿瘤/正常组织生物剂量8.46/2.57 Gy-Eq。
临床怎么用
- BNCT 250 mg/kg在临床前模型中显示肿瘤控制与神经保护双重优势,支持进一步优化剂量。
- BNCT 500 mg/kg虽抗肿瘤更强但未改善运动功能,提示需关注正常组织耐受性。
局限性
- 研究仅在小鼠原位胶质瘤模型中进行,结论外推至临床需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Boron Neutron Capture Therapy (BNCT) offers precise tumor targeting in brain tumor treatment. However, its anti-glioma mechanism remains unclear, and radiation safety requires strict dose optimization. PURPOSE: To define the safe therapeutic window for BNCT in the treatment of glioma and elucidate tumor-control mechanisms. METHODS: In vitro: GL261 cell viability assessed via CCK-8 and colony formation assays under varying 10B-BPA concentrations and neutron irradiation durations. In vivo: Orthotopic GL261 glioma models established. Treatment efficacy evaluated by tumor weight, survival analysis, and body weight monitoring. Boron biodistribution measured by ICP-MS. Motor/cognitive function assessed via open field and novel object recognition tests. Key protein expression analyzed by Western blotting in tumors/normal brain tissue. RESULTS: In vitro, 10B-BPA alone was non-cytotoxic, but significantly enhanced tumor cell killing when combined with neutron irradiation. In vivo, BNCT treatment (with 10B-BPA dose of 250, [BNCT 250] or 500 mg/kg, [BNCT 500]) reduced tumor weight more effectively than neutron irradiation alone, confirming its enhanced anti-tumor effect. However, only the BNCT 250 alleviated motor impairment in mice. Photon-equivalent dose estimation revealed tumor/normal tissue biological doses of 4.43/1.42 Gy-Eq for BNCT 250 and 8.46/2.57 Gy-Eq for BNCT 500. Furthermore, BNCT 250 significantly increased NeuN and BDNF expression in normal brain tissue and promoted tumor apoptosis by elevating the Bax/Bcl-2 ratio, inducing cytochrome c release, and activating the caspase cascade. CONCLUSION: Optimal BNCT regimen selectively triggered mitochondrial apoptosis in tumors via Bax/Bcl2/caspase cascade, while upregulating NeuN/BDNF in normal brains. This study firstly verified dual tumor control and neuroprotective efficacy of BNCT in vivo.
引用
- Gao F, Huang H, Zuo D, et al. Dual tumor control and neuroprotective efficacy of Boron Neutron Capture Therapy in orthotopic mouse glioma model. J Neurooncol. 2025. PMID: 41199086. doi:10.1007/s11060-025-05286-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。